Urovant Sciences Ltd. (NASDAQ:UROV) is reporting first quarter financial results on Thursday 13th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, UROV is expected to report 1Q20 loss of $ 1.39 per share
For the full year, analysts anticipate top line of $ 4.30 million, while looking forward to loss of $ 7.13 per share bottom line.
Previous Quarter Performance
Urovant Sciences Ltd. announced loss for the fourth quarter of $ 1.68 per share, from the revenue of . The consensus estimates are loss of $ 1.24 per share The bottom line results missed street analysts by $ 0.44 or 35.48 percent, at the same time, top line results analysts by $ 4.32 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of UROV was $ 7.67, representing a 17.10 % increase from the 52 week low of $ 6.55 and a 52 % decrease over the 52 week high of $ 15.98.
The company has a market capital of $ 239.16 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”UROV” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 19th June 2020, maintained by HC Wainwright at Buy rating, with $ 28.00 target price.
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd.
